AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Overview | Financials
Company Name AN2 Therapeutics, Inc.
Symbol ANTX
Currency USD
Price 1.08
Market Cap 32,229,824
Dividend Yield 0%
52-week-range 0.87 - 22.22
Industry Biotechnology
Sector Healthcare
CEO Mr. Eric E. Easom
Website https://www.an2therapeutics.com

An error occurred while fetching data.

About AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.

Related Stocks

Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc.

TNYA

1.91 USD

ESSA Pharma Inc. logo

ESSA Pharma Inc.

EPIX

5.74 USD

AC Immune SA logo

AC Immune SA

ACIU

3.11 USD

Precigen, Inc. logo

Precigen, Inc.

PGEN

0.937 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

33.39 USD

Lexicon Pharmaceuticals, Inc. logo

Lexicon Pharmaceuticals, Inc.

LXRX

1.94 USD

Alpine Immune Sciences, Inc. logo

Alpine Immune Sciences, Inc.

ALPN

64.97 USD

Financials

Numbers are in millions USD

Numbers are in millions USD